K. Yoshimatsu, M. Satake, Masaki Matsumura, Yoshitomo Ito, R. Imaizumi, T. Koike, H. Yokomizo, Tatsuro Yamaguchi, S. Shiozawa
{"title":"一例转移性癌症伴RAS野生瘤患者在mFOLFOX6加帕尼单抗治疗期间进展","authors":"K. Yoshimatsu, M. Satake, Masaki Matsumura, Yoshitomo Ito, R. Imaizumi, T. Koike, H. Yokomizo, Tatsuro Yamaguchi, S. Shiozawa","doi":"10.4993/acrt.27.67","DOIUrl":null,"url":null,"abstract":"We herein report a case of metastatic colon cancer RAS wild tumor progressed during the treatment with FOLFOX + panitumumab and then recognized as BRAF mutation and MSI-H. Seventy eight years-old male patient showed anastomotic recurrence of colon cancer after curative resection of Stage II ascending colon cancer six years before the appearance of the recurrence. Six months after R0 resection, surveillance CT was performed and diagnosed as recurrent tumor invaded to duodenum. For R0 resection, mFOLFOX6 plus panitumumab therapy was initiated to expect early tumor shrinkage because of RAS wild tumor. However, tumor progressed after 4 cycles. The second-line therapy was not able to started because the disease progression was extremely rapid. He died 4 months after initiation of therapy. BRAF mutation and MSI-H were recognized from his tumor by the additional analyses.","PeriodicalId":35647,"journal":{"name":"Annals of Cancer Research and Therapy","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A case of metastatic colon cancer with RAS wild tumor progressed during the treatment with mFOLFOX6 plus panitumumab\",\"authors\":\"K. Yoshimatsu, M. Satake, Masaki Matsumura, Yoshitomo Ito, R. Imaizumi, T. Koike, H. Yokomizo, Tatsuro Yamaguchi, S. Shiozawa\",\"doi\":\"10.4993/acrt.27.67\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"We herein report a case of metastatic colon cancer RAS wild tumor progressed during the treatment with FOLFOX + panitumumab and then recognized as BRAF mutation and MSI-H. Seventy eight years-old male patient showed anastomotic recurrence of colon cancer after curative resection of Stage II ascending colon cancer six years before the appearance of the recurrence. Six months after R0 resection, surveillance CT was performed and diagnosed as recurrent tumor invaded to duodenum. For R0 resection, mFOLFOX6 plus panitumumab therapy was initiated to expect early tumor shrinkage because of RAS wild tumor. However, tumor progressed after 4 cycles. The second-line therapy was not able to started because the disease progression was extremely rapid. He died 4 months after initiation of therapy. BRAF mutation and MSI-H were recognized from his tumor by the additional analyses.\",\"PeriodicalId\":35647,\"journal\":{\"name\":\"Annals of Cancer Research and Therapy\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-07-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Cancer Research and Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4993/acrt.27.67\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Cancer Research and Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4993/acrt.27.67","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
A case of metastatic colon cancer with RAS wild tumor progressed during the treatment with mFOLFOX6 plus panitumumab
We herein report a case of metastatic colon cancer RAS wild tumor progressed during the treatment with FOLFOX + panitumumab and then recognized as BRAF mutation and MSI-H. Seventy eight years-old male patient showed anastomotic recurrence of colon cancer after curative resection of Stage II ascending colon cancer six years before the appearance of the recurrence. Six months after R0 resection, surveillance CT was performed and diagnosed as recurrent tumor invaded to duodenum. For R0 resection, mFOLFOX6 plus panitumumab therapy was initiated to expect early tumor shrinkage because of RAS wild tumor. However, tumor progressed after 4 cycles. The second-line therapy was not able to started because the disease progression was extremely rapid. He died 4 months after initiation of therapy. BRAF mutation and MSI-H were recognized from his tumor by the additional analyses.